<DOC>
	<DOCNO>NCT02690909</DOCNO>
	<brief_summary>The ReDy™ System ( Renal Dynamics ) renal denervation device incorporate variety ablation feature technical improvement previously design system single product . It intend treat uncontrolled ( drug-resistant ) hypertension RF ablation sympathetic nerve network surround renal artery . This study carry validate safety efficacy ReDy™ Renal Denervation device demonstrate performs accord intend use , i.e . treatment patient uncontrolled hypertension .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Redy™ Renal Denervation System Treatment Patients With Uncontrolled Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<criteria>Inclusion criterion : 1 . Patient establish hypertension ( diagnose ≥12 month prior screen ) guideline base stable drug regimen ( ≥ 4 week ) , consist ≥3 antihypertensive medication different class include diuretic ; 2 . Office systolic blood pressure &gt; 150 mmHg ; 3 . Patient ( directly observe therapy ) average daytime systolic blood pressure value &gt; 140 mmHg 24h ambulatory blood pressure monitoring ; 4 . Patient ≥ 18 ≤ 75 year age time consent ; 5 . Patient must able willing comply require followup schedule ; 6 . Patient must able willing provide write informed consent ; Exclusion criterion : 1 . Patient known significant renovascular abnormality renal artery stenosis &gt; 30 % ; 2 . Patient `` Isolated Systolic Hypertension '' diastolic blood pressure &lt; 90 mmHg ; 3 . Evidence history secondary hypertension , sleep apnea syndrome ; 4 . Patient history prior renal angioplasty , renal denervation , indwell renal stent , and/or abdominal aortic stent graft placement ; 5 . Patient significant valvular heart disease ; 6 . Patient known coagulation abnormality ; 7 . Patient life expectancy &lt; 12 month , estimate study Investigator ; 8 . Patient participate another clinical study , primary endpoint and/or potential impact his/her hypertension management ( pharmaceutical / device ) ; 9 . Patient pregnant , nursing , childbearing potential use adequate contraceptive method ; 10 . Patient active systemic infection ; 11 . Patient small &lt; 4.0 mm diameter , large &gt; 6.5 mm diameter short &lt; 20.0 mm length , multiple main , highly tortuous renal artery ; 12 . Patient impair renal function estimate GFR &lt; 45 mL/min per 1.73 m2 use Modification Diet Renal Disease ( MDRD ) formula ; 13 . Patient renal transplant await renal transplant ; 14 . Patient known intolerance xray contrast agent adequately controlled premedication ; 15 . Any medical condition estimate Study Investigator may harm patient jeopardize study participation , interpretation study result may impede ability obtain informed consent ( e.g. , mental condition ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Uncontrolled Hypertension</keyword>
	<keyword>Resistant Hypertension</keyword>
	<keyword>Renal Denervation</keyword>
</DOC>